Abstract: A method of purifying adipose-derived mesenchymal stem cells from a sample of adipose tissue, including: flowing the sample onto a polymer surface having at least one vertical helical-shaped portion, vertical threaded shaped portion, or vertical grooved shaped portion at a first flow rate of 10 to 150 ml/min allowing separation into a first remaining sample including mesenchymal stem cells on the polymer surface and into a second resulting solution being evacuated from the polymer surface; flowing a saline solution onto the polymer surface at a second flow rate of 100 to 500 ml/min, the first flow rate being slower than the second flow rate; and collecting the saline solution including purified mesenchymal stem cells in a collector. Also, an apparatus and a system for purifying adipose-derived mesenchymal stem cells, the use of the apparatus, and a method of isolating and purifying adipose-derived mesenchymal stem cells from an adipose tissue sample.
Abstract: A method for purifying and enriching mesenchymal stem cells (MSCs) simply and efficiently. Separation of cells expressing CD73 protein on the surface from fresh tissue isolated from a living body allows purification and enrichment of MSCs easily and efficiently. MSCs may be selectively isolated with a single antibody before culturing to establish a culture system of mesenchymal stem cells that enhances the engraftment efficiency in the transplanted site.
Type:
Grant
Filed:
May 11, 2018
Date of Patent:
March 28, 2023
Assignees:
Medical & Biological Laboratories Co., Ltd., JSR Corporation
Inventors:
Chihiro Akazawa, Eriko Grace Suto, Yo Mabuchi
Abstract: A method of efficiently recovering a large amount of exosomes from mesenchymal stem cells is provided. The method includes: a three dimensional culture step of three dimensionally culturing mesenchymal stem cells in a medium containing sugar by using a nonwoven fabric as a scaffold; a post-plateau culture step of further culturing for a certain period of time after the amount of the sugar consumed by the mesenchymal stem cells reaches a plateau; and an exosome recovery step of recovering exosomes from the mesenchymal stem cells. The mesenchymal stem cells are adipose-derived mesenchymal stem cells.
Abstract: A fibrous birth tissue composition fabricated from placental tissue is provided. Methods of processing a mammal's placental tissue to form a fibrous birth tissue composition are provided. Regenerative methods are also provided.
Abstract: There is provided a sorbent for removing metabolic waste products from a dialysis liquid, the sorbent comprising a layer of immobilized uremic toxin-treating enzyme particles intermixed with cation exchange particles.
Type:
Grant
Filed:
February 17, 2020
Date of Patent:
February 28, 2023
Assignee:
TEMASEK POLYTECHNIC
Inventors:
Christian Gert Bluchel, Yanmei Wang, Kim Cheng Tan
Abstract: Provided herein is technology relating to engineered tissues and particularly, but not exclusively, to methods, compositions, and systems for engineering a biosynthetic vascular network.
Type:
Grant
Filed:
December 5, 2017
Date of Patent:
February 14, 2023
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Abstract: The presently disclosed subject matter provides for in vitro methods of inducing differentiation of stem cells (e.g., human stem cells) into proprioceptors, proprioceptors generated by such methods, and compositions comprising such proprioceptors. The presently disclosed subject matter also provides for uses of such proprioceptors for preventing and/or treating disorders of proprioceptor neurons and/or neurodegenerative disorders (e.g., Friedreich's Ataxia).
Abstract: Provided is a method for knocking in a gene of interest to a cell. The genome of the cell contains a negative selectable marker, e.g., a thymidine kinase gene flanked by a pair of recombinase recognition sites (RRS), e.g., attP. The method involves introducing into the cell a targeting construct that contains a gene of interest flanked by a second pair of RRS, e.g., attB. The targeting construct also contains in the vector backbone a negative selectable marker, e.g., thymidine kinase gene. When a recombinase recognizing the RRS is expressed, the recombination events between the two pairs of RRS result in the site-specific integration of the gene of interest in the genome of the cell. Upon selection based on the negative selectable marker, the parental cells, cells with undesired integration, e.g., random integration, or the integration of the vector backbone are removed.
Abstract: The present invention is directed to a dry pad comprising pectin, a divalent cation and thrombin and to its preparation. Preferably, the density of pectin in the dry pad of the invention ranges from about equal to or higher than 1% to lower than 7% (w/v). The pad according to the invention comprises pectin having a low methoxyl content.
Abstract: The present disclosure relates to methods of preparing personalized blood vessels, useful for transplantation with improved host compatibility and reduced susceptibility to thrombosis. Also provided are personalized blood vessels produced by the methods and use thereof in surgery.
Abstract: The present invention is in the field of the cultivation of biological cells and tissues with organ-like function on a microphysiological scale and provides a method for the microphysiological co-cultivation of 3D organoid tissue and at least one 2D cell layer.
Type:
Grant
Filed:
October 1, 2018
Date of Patent:
October 4, 2022
Assignee:
EBERHARD KARLS UNIVERSITÄT TÜBINGEN
Inventors:
Peter Loskill, Christopher Probst, Stefan Liebau, Kevin Achberger, Jasmin Haderspeck
Abstract: The present invention provides a method of producing an osteoblast construct from human iPS cells, the method including the steps of: (1) inducing formation of an embryoid body by subjecting undifferentiated human iPS cells to non-adherent culture; (2) inducing differentiation of the human iPS cells into mesodermal cells by subjecting the embryoid body of the human iPS cells obtained in the step (1) to non-adherent culture; and (3) inducing differentiation into osteoblasts by subjecting the mesodermal cells of the human iPS cells obtained in the step (2) to non-adherent culture.
Abstract: Methods are provided for extracting bone marrow cells from bone obtained from deceased donors, for preparing the bone marrow for cryopreservation and for obtaining desired cells from cryopreserved and fresh bone marrow.
Type:
Grant
Filed:
September 4, 2020
Date of Patent:
September 20, 2022
Assignee:
Ossium Health, Inc.
Inventors:
Erik John Woods, Brian H. Johnstone, Dongsheng Gu, Aubrey Marie Sherry, Kelsey Gwen Musall, John R. Woods, James Hardin, Alan Hooks
Abstract: The invention relates to biologically functional scaffolds having a porous structure, methods of preparing, and methods of use thereof. The invention also relates to methods of repairing a defect, methods of culturing cells and promoting differentiation of stem cells using the same.
Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
Abstract: An organ-on-a-chip microfluidic device is disclosed that mimics a human lymph node and/or human lymphoid tissue. The device can include cells from human blood and lymphatic tissue, include an extracellular matrix for the development of immune system components, and provide for the perfusion of fluids and solids resembling blood and lymphatic fluid within micrometer sized channels.
Type:
Grant
Filed:
July 18, 2017
Date of Patent:
August 9, 2022
Assignee:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Abstract: The present technology relates to a method of augmenting soft facial tissue in a human subject using a liquid suspension including amnion allograft. Analysis of the changes to midface volume, specifically the Ogee curve, observed in the chronological progression of photographs illustrates aesthetic improvements in both Platelet Rich Plasma (PRP) and amnion allograft treatment groups, with changes in the facial grading scale. Less patient downtime and slightly more rapid improvements were noted in the amnion group in comparison to PRP treatment participants. As a result, the amnion allograft provides advantages over the PRP procedure.
Abstract: Embodiments of a method of modulating a potency level phenotype of a source population of cells include culturing the source cell population in a liquid medium within a cell culture incubator, the incubator is configured to independently regulate one or more variable parameters of gaseous conditions within the incubator, the more than one variable atmospheric parameters within the incubator being regulated independently of each other and independently of ambient external gaseous conditions. The method further includes regulating the one or more variable parameters of the gaseous condition within the incubator such that at least one of the one or more variable parameter differs from an ambient level of the respective variable parameter, and as a consequence of such difference from ambient conditions, the subset population is driven from a first potency level phenotype to a second potency level phenotype.
Type:
Grant
Filed:
December 18, 2018
Date of Patent:
June 21, 2022
Assignee:
XCELL BIOSCIENCES, INC.
Inventors:
James Lim, Bruce Adams, Zack Pappalardo, Brian Feth
Abstract: Provided is a new type serum-free medium. The medium comprises: DMEM with high glucose (the content of glucose being 4.5 g/L), B27, recombinant human basic fibrolast growth factor (b-FGF), nicotinamide, N-2, vinblastine III (conophylline), non-essential amino acid (NEAA), heparin, epidermal growth factor (EGF), hepatocyte growth factor (HGF), a serum replacement (SR), an insulin-transferrin-selenium complex (ITS), and pentagastrin. Inducing differentiation of mesenchymal stem cells into insulin-secretion-like cells can be achieved in six days in one step using the medium.
Abstract: Devices and techniques for magnetic detection of myocardial forces are generally described. In some examples, cardiac tissue may be cultured such that the cardiac tissue adheres to a first post and a second post. In further examples, a magnetometer may detect a change in a magnetic field resulting from a deflection of the first post in a first direction from a first position to a second position. In some other examples a signal corresponding to the change in the magnetic field may be generated. In still other examples, frequencies of the signal outside of a first frequency range may be excluded to produce a filtered signal. In various examples, the first frequency range may include frequencies associated with beating of cardiac tissue. In still further examples, a force exerted by the cardiac tissue may be determined based at least in part on the filtered signal.
Type:
Grant
Filed:
March 10, 2017
Date of Patent:
May 17, 2022
Assignee:
University of Washington
Inventors:
Nathan J. Sniadecki, Shiv Bhandari, Kevin S. Bielawski, Andrea B. Leonard, Charles E. Murry